226 related articles for article (PubMed ID: 19035362)
1. Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome.
Rosenberger G; Meien S; Kutsche K
Hum Mutat; 2009 Mar; 30(3):352-62. PubMed ID: 19035362
[TBL] [Abstract][Full Text] [Related]
2. Functional analysis of a duplication (p.E63_D69dup) in the switch II region of HRAS: new aspects of the molecular pathogenesis underlying Costello syndrome.
Lorenz S; Lissewski C; Simsek-Kiper PO; Alanay Y; Boduroglu K; Zenker M; Rosenberger G
Hum Mol Genet; 2013 Apr; 22(8):1643-53. PubMed ID: 23335589
[TBL] [Abstract][Full Text] [Related]
3. Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation.
Gremer L; De Luca A; Merbitz-Zahradnik T; Dallapiccola B; Morlot S; Tartaglia M; Kutsche K; Ahmadian MR; Rosenberger G
Hum Mol Genet; 2010 Mar; 19(5):790-802. PubMed ID: 19995790
[TBL] [Abstract][Full Text] [Related]
4. HRAS mutants identified in Costello syndrome patients can induce cellular senescence: possible implications for the pathogenesis of Costello syndrome.
Niihori T; Aoki Y; Okamoto N; Kurosawa K; Ohashi H; Mizuno S; Kawame H; Inazawa J; Ohura T; Arai H; Nabatame S; Kikuchi K; Kuroki Y; Miura M; Tanaka T; Ohtake A; Omori I; Ihara K; Mabe H; Watanabe K; Niijima S; Okano E; Numabe H; Matsubara Y
J Hum Genet; 2011 Oct; 56(10):707-15. PubMed ID: 21850009
[TBL] [Abstract][Full Text] [Related]
5. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
Nava C; Hanna N; Michot C; Pereira S; Pouvreau N; Niihori T; Aoki Y; Matsubara Y; Arveiler B; Lacombe D; Pasmant E; Parfait B; Baumann C; Héron D; Sigaudy S; Toutain A; Rio M; Goldenberg A; Leheup B; Verloes A; Cavé H
J Med Genet; 2007 Dec; 44(12):763-71. PubMed ID: 17704260
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor up-regulates expression of transforming growth factor beta receptor type II in human dermal fibroblasts by phosphoinositide 3-kinase/Akt signaling pathway: Resistance to epidermal growth factor stimulation in scleroderma fibroblasts.
Yamane K; Ihn H; Tamaki K
Arthritis Rheum; 2003 Jun; 48(6):1652-66. PubMed ID: 12794834
[TBL] [Abstract][Full Text] [Related]
7. An attenuated phenotype of Costello syndrome in three unrelated individuals with a HRAS c.179G>A (p.Gly60Asp) mutation correlates with uncommon functional consequences.
Gripp KW; Sol-Church K; Smpokou P; Graham GE; Stevenson DA; Hanson H; Viskochil DH; Baker LC; Russo B; Gardner N; Stabley DL; Kolbe V; Rosenberger G
Am J Med Genet A; 2015 Sep; 167A(9):2085-97. PubMed ID: 25914166
[TBL] [Abstract][Full Text] [Related]
8. HRAS and the Costello syndrome.
Rauen KA
Clin Genet; 2007 Feb; 71(2):101-8. PubMed ID: 17250658
[TBL] [Abstract][Full Text] [Related]
9. Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
Schulz AL; Albrecht B; Arici C; van der Burgt I; Buske A; Gillessen-Kaesbach G; Heller R; Horn D; Hübner CA; Korenke GC; König R; Kress W; Krüger G; Meinecke P; Mücke J; Plecko B; Rossier E; Schinzel A; Schulze A; Seemanova E; Seidel H; Spranger S; Tuysuz B; Uhrig S; Wieczorek D; Kutsche K; Zenker M
Clin Genet; 2008 Jan; 73(1):62-70. PubMed ID: 18042262
[TBL] [Abstract][Full Text] [Related]
10. C4ST-1/CHST11-controlled chondroitin sulfation interferes with oncogenic HRAS signaling in Costello syndrome.
Klüppel M; Samavarchi-Tehrani P; Liu K; Wrana JL; Hinek A
Eur J Hum Genet; 2012 Aug; 20(8):870-7. PubMed ID: 22317973
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of the PI3-kinase/Akt pathway by ERK MAP kinase in growth factor signaling.
Hayashi H; Tsuchiya Y; Nakayama K; Satoh T; Nishida E
Genes Cells; 2008 Sep; 13(9):941-7. PubMed ID: 18691227
[TBL] [Abstract][Full Text] [Related]
12. HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy.
Estep AL; Tidyman WE; Teitell MA; Cotter PD; Rauen KA
Am J Med Genet A; 2006 Jan; 140(1):8-16. PubMed ID: 16372351
[TBL] [Abstract][Full Text] [Related]
13. Signal transduction of MEK/ERK and PI3K/Akt activation by hypoxia/reoxygenation in renal epithelial cells.
Kwon DS; Kwon CH; Kim JH; Woo JS; Jung JS; Kim YK
Eur J Cell Biol; 2006 Nov; 85(11):1189-99. PubMed ID: 16860436
[TBL] [Abstract][Full Text] [Related]
14. Somatic mosaicism for an HRAS mutation causes Costello syndrome.
Gripp KW; Stabley DL; Nicholson L; Hoffman JD; Sol-Church K
Am J Med Genet A; 2006 Oct; 140(20):2163-9. PubMed ID: 16969868
[TBL] [Abstract][Full Text] [Related]
15. Craniofacial and dental development in Costello syndrome.
Goodwin AF; Oberoi S; Landan M; Charles C; Massie JC; Fairley C; Rauen KA; Klein OD
Am J Med Genet A; 2014 Jun; 164A(6):1425-30. PubMed ID: 24668879
[TBL] [Abstract][Full Text] [Related]
16. Attenuated phenotype of Costello syndrome and early death in a patient with an HRAS mutation (c.179G>T; p.Gly60Val) affecting signalling dynamics.
Gripp KW; Kolbe V; Brandenstein LI; Rosenberger G
Clin Genet; 2017 Sep; 92(3):332-337. PubMed ID: 28139825
[TBL] [Abstract][Full Text] [Related]
17. EGF-induced cell migration is mediated by ERK and PI3K/AKT pathways in cultured human lens epithelial cells.
Jiang Q; Zhou C; Bi Z; Wan Y
J Ocul Pharmacol Ther; 2006 Apr; 22(2):93-102. PubMed ID: 16722795
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive genetic analysis of overlapping syndromes of RAS/RAF/MEK/ERK pathway.
Tumurkhuu M; Saitoh M; Sato A; Takahashi K; Mimaki M; Takita J; Takeshita K; Hama T; Oka A; Mizuguchi M
Pediatr Int; 2010 Aug; 52(4):557-62. PubMed ID: 20030748
[TBL] [Abstract][Full Text] [Related]
19. Germline mutations in HRAS proto-oncogene cause Costello syndrome.
Aoki Y; Niihori T; Kawame H; Kurosawa K; Ohashi H; Tanaka Y; Filocamo M; Kato K; Suzuki Y; Kure S; Matsubara Y
Nat Genet; 2005 Oct; 37(10):1038-40. PubMed ID: 16170316
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition.
MacKeigan JP; Taxman DJ; Hunter D; Earp HS; Graves LM; Ting JP
Clin Cancer Res; 2002 Jul; 8(7):2091-9. PubMed ID: 12114408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
